Premium
Granulomatous/sarcoid‐like reactions in the setting of programmed cell death‐1 inhibition: a potential mimic of disease recurrence
Author(s) -
Hiraki Tsubasa,
Hatanaka Miho,
Arimura Akiko,
Kawahira Hisao,
Kirishima Mari,
Kitazono Ikumi,
Horinouchi Michiko,
Higashi Michiyo,
Kanekura Takuro,
Tanimoto Akihide
Publication year - 2020
Publication title -
journal of cutaneous pathology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.597
H-Index - 75
eISSN - 1600-0560
pISSN - 0303-6987
DOI - 10.1111/cup.13569
Subject(s) - pembrolizumab , nivolumab , medicine , immunotherapy , malignancy , melanoma , adverse effect , pathology , disease , biopsy , ipilimumab , immune system , dermatology , immunology , cancer research
Nivolumab and pembrolizumab are humanized IgG4 monoclonal antibodies against programmed cell death 1 (PD‐1). Although these agents are effective in treating advanced melanoma, non‐small‐cell lung carcinoma, and other types of cancers, various adverse events have been reported. Cutaneous adverse events are particularly prevalent and, while granulomatous/sarcoid‐like reactions are uncommon, they are increasingly recognized as immune‐related adverse events associated with immune checkpoint inhibitors. Herein, we report two cases of granulomatous/sarcoid‐like reaction with foreign material, mimicking metastatic malignancy after PD‐1 inhibitor treatment. Clinicians should be aware of the existence of cutaneous lesions and perform biopsy if needed to prevent misdiagnosis and unnecessary adjustments to immunotherapy.